Cargando…
Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer’s Disease
Alzheimer’s disease (AD) is a commonly occurring neurodegenerative disease in the advanced-age population, with a doubling of prevalence for each 5 years of age above 60 years. In the past two decades, there has been a sustained effort to find suitable biomarkers that may not only aide with the diag...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563364/ https://www.ncbi.nlm.nih.gov/pubmed/32708853 http://dx.doi.org/10.3390/jpm10030063 |
_version_ | 1783595472813817856 |
---|---|
author | Omar, Syed Haris Preddy, John |
author_facet | Omar, Syed Haris Preddy, John |
author_sort | Omar, Syed Haris |
collection | PubMed |
description | Alzheimer’s disease (AD) is a commonly occurring neurodegenerative disease in the advanced-age population, with a doubling of prevalence for each 5 years of age above 60 years. In the past two decades, there has been a sustained effort to find suitable biomarkers that may not only aide with the diagnosis of AD early in the disease process but also predict the onset of the disease in asymptomatic individuals. Current diagnostic evidence is supportive of some biomarker candidates isolated from cerebrospinal fluid (CSF), including amyloid beta peptide (Aβ), total tau (t-tau), and phosphorylated tau (p-tau) as being involved in the pathophysiology of AD. However, there are a few biomarkers that have been shown to be helpful, such as proteomic, inflammatory, oral, ocular and olfactory in the early detection of AD, especially in the individuals with mild cognitive impairment (MCI). To date, biomarkers are collected through invasive techniques, especially CSF from lumbar puncture; however, non-invasive (radio imaging) methods are used in practice to diagnose AD. In order to reduce invasive testing on the patients, present literature has highlighted the potential importance of biomarkers in blood to assist with diagnosing AD. |
format | Online Article Text |
id | pubmed-7563364 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75633642020-10-27 Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer’s Disease Omar, Syed Haris Preddy, John J Pers Med Review Alzheimer’s disease (AD) is a commonly occurring neurodegenerative disease in the advanced-age population, with a doubling of prevalence for each 5 years of age above 60 years. In the past two decades, there has been a sustained effort to find suitable biomarkers that may not only aide with the diagnosis of AD early in the disease process but also predict the onset of the disease in asymptomatic individuals. Current diagnostic evidence is supportive of some biomarker candidates isolated from cerebrospinal fluid (CSF), including amyloid beta peptide (Aβ), total tau (t-tau), and phosphorylated tau (p-tau) as being involved in the pathophysiology of AD. However, there are a few biomarkers that have been shown to be helpful, such as proteomic, inflammatory, oral, ocular and olfactory in the early detection of AD, especially in the individuals with mild cognitive impairment (MCI). To date, biomarkers are collected through invasive techniques, especially CSF from lumbar puncture; however, non-invasive (radio imaging) methods are used in practice to diagnose AD. In order to reduce invasive testing on the patients, present literature has highlighted the potential importance of biomarkers in blood to assist with diagnosing AD. MDPI 2020-07-17 /pmc/articles/PMC7563364/ /pubmed/32708853 http://dx.doi.org/10.3390/jpm10030063 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Omar, Syed Haris Preddy, John Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer’s Disease |
title | Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer’s Disease |
title_full | Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer’s Disease |
title_fullStr | Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer’s Disease |
title_full_unstemmed | Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer’s Disease |
title_short | Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer’s Disease |
title_sort | advantages and pitfalls in fluid biomarkers for diagnosis of alzheimer’s disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563364/ https://www.ncbi.nlm.nih.gov/pubmed/32708853 http://dx.doi.org/10.3390/jpm10030063 |
work_keys_str_mv | AT omarsyedharis advantagesandpitfallsinfluidbiomarkersfordiagnosisofalzheimersdisease AT preddyjohn advantagesandpitfallsinfluidbiomarkersfordiagnosisofalzheimersdisease |